Search

Background: Non-carcinoid appendix epithelial tumors are rare. These tumors include low-grade and high-grade mucinous neoplasm also adenocarcinomas. We aimed to investigate the clinicopathological features, treatment, and risk factors of recurrence. Methods: Patients diagnosed between 2008 and 2019 were retrospectively analyzed. Categorical variables were expressed as percentages and compared using the Chi-square test or Fisher's exact tests. Overall survival and Disease-free survival of the groups were calculated by the Kaplan-Meier method, and the log-rank test was used to compare the survival rates. Results: A total of 35 patients were included in the study. Of the patients, 19 (54%) were women and the median diagnosis age of patients was 50.4 years (19-76). As for pathological types, a total of 14 (40%) patients were mucinous adenocarcinoma and 14 (40%) patients were Low-Grade Mucinous Neoplasm (LGMN). Lymph node excision and lymph node involvement were 23 (65%) and 9 (25%) patients respectively. The majority of patients were stage 4 (27, 79%) and 25 (71%) of these patients had peritoneal metastasis. A total of 48.6% patients had been treated with cytoreductive surgery and hyper-thermic intraperitoneal chemotherapy. Median Peritoneal cancer index value was 12 (2-36). The median follow-up time was 20 (1-142) months. Recurrence developed in 12 (34%) of patients. When risk factors for recurrence are considered, there was a statistically significant difference in appendix tumors with high-grade, adenocarcinoma pathology, ones with peritoneal cancer index ≥12 and not having pseudomyxoma peritonei. Median disease-free survival was 18 (13-22, 95% CI) months. Median overall survival could not be reached while the 3-year survival rate was 79%. Conclusion: The risk of recurrence is higher in high-grade appendix tumors, having peritoneal cancer index ≥ 12, not having pseudomyxoma peritonei and adenocarcinoma pathology. High-grade appendix adenocarcinoma patients should be followed closely for recurrence. Keywords: Adenocarcinoma, appendiceal neoplasm, mucinous neoplasm, pseudomyxoma peritonei, Author(s): Ozturk Ates (corresponding author) [1]; Bulent Aksel [2]; Ibrahim Karadag [1]; Serdar Karakaya [1]; Veli Sunar [3]; O. Berna Oksuzoglu [1] Background Appendix tumors are very rare and constitute [...]

Objectives: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). Methods: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed. Results: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8–9.8) in the G-CSF group and 6.8 months (95% CI, 6.2–7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6–18.1) for the G-CSF group and 10.6 months (95% CI, 7.9–13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12). Conclusion: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity. [ABSTRACT FROM AUTHOR]

Aims. The aim of this study was to evaluate the association between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and microalbuminuria in patients with normal estimated glomerular filtration rate (eGFR).

It was aimed to investigate the relationship between liver fibrosis and liver metastasis by using AST to Platelet Ratio Index (APRI) and Fibrosis4 (FIB4) non-invasive hepatic fibrosis scorings at the time of diagnosis in patients with nonmetastatic colorectal cancers (CRC) at diagnosis. A total of 1452 patients with colorectal cancer who were followed up between 2015-2020 were retrospectively reviewed. Seven hundred and fifty eight patients were included in the study. Fifty four patients who devoloped liver metastatis were compared with 704 patients who did not develop metastasis, the mean APRI score and mean FIB4 score at the time of diagnosis was determined to be significantly higher in the group with liver metastasis. The area under the curve (AUC) for the APRI score was 0.735 and the optimum sensitivity for detecting liver metastasis was 75.9%, while the optimal specificity was 65.1% and for the FIB4 score, AUC was 0.738, the optimum sensitivity for detecting liver metastasis was 74.1% and the specificity was 67.4%. When multivariate logistic regression analysis was conducted, FIB4 score, APRI score, Tstage, and Nstage were found as independent predictive factors in predicting liver metastasis It has been demonstrated that the group that may develop liver metastasis among patients with non-metastatic CRC at the time of diagnosis could be predicted by using the noninvasive liver fibrosis markers FIB4 and APRI scores. Moreover, it has been shown that these two scorings are also independent predictive markers. Based on this, shorter surveillance intervals may be an option in the group with higher FIB4 and APRI scores at the time of diagnosis. [ABSTRACT FROM AUTHOR]

Purpose: Recently, neoadjuvant treatment approach has gained importance in locally advanced HER-2 positive breast cancer. Adding pertuzumab increases pathological complete response (pCR). In this study, we aimed to examine the clinicopathologic features that predict the pCR in patients receiving neoadjuvant pertuzumab, trastuzumab, and chemotherapy in locally advanced HER2 positive breast cancer., Methods: Locally advanced HER2 positive breast cancer patients who were followed up in 4 different oncology centers and received 4 cycles of pertuzumab, trastuzumab and taxane were retrospectively evaluated. A total of 58 (92%) patients received anthracycline chemotherapy before combination of dual her-2 blockade and taxanes. Fisher's and chi-square tests were used for nominal variables and numeric data analyses., Results: A total of 63 female patients were included in the study. Their median age was 46 years (21-75) and 40 (63.5%) patients were premenopausal. Median tumor size was 25 mm (2-70) and there were 22 (34.9%) patients with Stage 3a. pCR was 66% and 75% in the whole group and in the hormone negative group, respectively. Statistically significant increase was found in pCR in patients with grade 3 tumors and cerbB2 with 3+ immunohistochemical staining. No relationship was found between pCR and age at diagnosis, menopausal status, tumor infiltrating lymphocyte, dose-dense anthracycline, Ki67≥40, body mass index (BMI) ≥ 30 kg/m2 and accompanying DCIS., Conclusion: Four cycles of pertuzumab, trastuzumab and taxane after neoadjuvant anthracycline for locally advanced HER2 breast cancer are associated with increased pCR in patients with grade 3 tumors and high cerbB2 expression.